Bamlanivimab is a recombinant neutralizing human IgG1K monoclonal antibody (mAb) to the spike protein of SARS-CoV-2 and is unmodified in the Fc region. Etesevimab is a recombinant neutralizing human IgG1K mAb to the spike protein of SARS-CoV-2, with amino acid substitutions in the Fc region (L234A, L235A) to reduce effector function. Bamlanivimab and etesevimab bind to different but overlapping epitopes in the receptor binding domain (RBD) of the S-protein. Using both antibodies together is expected to reduce the risk of viral resistance.
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
|ETESEVIMAB Solution for injection
|FDA, National Drug Code (US)
|MPI, US: SPL/PLR
Bamlanivimab and Etesevimab is an active ingredient of these brands:
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.